PRESS RELEASE

KPI Therapeutics’ Non-Opiate Pain Drug Effective in Neuropathic Pain and Burn Pain

New pre-clinical data suggests CSP-4 offers greater potency when compared to gabapentin and pregabalin

SEATTLE, WA May 11, 2016-KPI Therapeutics, a clinical stage biotechnology company today announced new research showing its highly potent peptide drug CSP-4 to be effective in alleviating a broad spectrum of neuropathic pain indications as well as burn pain in animal models. Previous research has also shown effectiveness in chemotherapy-induced pain. The new data was presented by Jose Mercado, Ph.D. at the 35th Annual Scientific Meeting of the American Pain Society in Austin, TX. Dr. Mercado is a scientist at Kineta, Inc., KPI’s lead science partner.
The new data illustrate the efficacy and potency of CSP-4 in preclinical models when compared to therapeutically effective analgesic doses of gabapentin and pregabalin (Lyrica®), the most highly prescribed therapies approved for the treatment of neuropathic pain on the market today. Additionally, CSP-4 does not produce significant CNS side effects at analgesic doses suggesting that CSP-4 may have a greater therapeutic index (analgesic efficacy over CNS side effects) than currently available therapies.

“Our preclinical findings demonstrate that RglA analogs like CSP-4 may represent a novel class of therapeutics for neuropathic pain with greater potency than currently available therapies. And of particular interest is their demonstrated prevention of the maladaptive changes in the nervous system that may lead to neuropathic pain,” said Dr. Mercado.

“This represents an innovative strategy for preventing chronic neuropathic pain. A treatment that targets mechanisms which may lead to neuro-restorative effects following peripheral nerve injury while also alleviating pain is unparalleled,” added Charles Magness, President and CEO of KPI Therapeutics.

CSP-4 was well tolerated in these models and showed no signs of toxicity. KPI’s RglA analogs are highly selective for its target and do not present significant off-target activity.

ABOUT CONOPETIDES
KPI’s drug works by inhibiting a novel, genetically validated pain target in the peripheral nervous system. Given this mechanism of action, this drug is not expected to induce chemical dependency, tolerance or life-threatening side effects found with opioids.
KPI’s conopeptides are small analogs of RglA, a cone snail venom protein. CSP-4 produced analgesic effects in a capsaicin-injection induced pain model. Intradermal injection of capsaicin is an increasingly experimental neuropathic model in humans. The conopeptide program is being developed jointly with Kineta Inc.
ABOUT KPI THERAPEUTICS
KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website: kpitherapeutics.com

ABOUT KINETA
Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com

###
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Dan Eramian, Senior Vice President Communications and Investor Relations, KPI Therapeutics, Inc., deramian@kpitherapeutics.com 206-518-5566